Logo image of ICLR

ICON PLC (ICLR) Stock Fundamental Analysis

NASDAQ:ICLR - Nasdaq - IE0005711209 - Common Stock - Currency: USD

201.72  +3.6 (+1.82%)

After market: 201.72 0 (0%)

Fundamental Rating

5

Taking everything into account, ICLR scores 5 out of 10 in our fundamental rating. ICLR was compared to 57 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of ICLR get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on ICLR. These ratings could make ICLR a good candidate for value investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

ICLR had positive earnings in the past year.
ICLR had a positive operating cash flow in the past year.
In the past 5 years ICLR has always been profitable.
ICLR had a positive operating cash flow in each of the past 5 years.
ICLR Yearly Net Income VS EBIT VS OCF VS FCFICLR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

1.2 Ratios

ICLR has a better Return On Assets (4.35%) than 78.95% of its industry peers.
The Return On Equity of ICLR (7.65%) is better than 80.70% of its industry peers.
ICLR's Return On Invested Capital of 6.28% is fine compared to the rest of the industry. ICLR outperforms 78.95% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ICLR is significantly below the industry average of 9.61%.
The 3 year average ROIC (4.59%) for ICLR is below the current ROIC(6.28%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.35%
ROE 7.65%
ROIC 6.28%
ROA(3y)2.48%
ROA(5y)5.99%
ROE(3y)4.82%
ROE(5y)11.11%
ROIC(3y)4.59%
ROIC(5y)9.41%
ICLR Yearly ROA, ROE, ROICICLR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 10 20 30

1.3 Margins

With a decent Profit Margin value of 9.00%, ICLR is doing good in the industry, outperforming 77.19% of the companies in the same industry.
ICLR's Profit Margin has declined in the last couple of years.
ICLR has a better Operating Margin (13.77%) than 75.44% of its industry peers.
ICLR's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 29.65%, ICLR is doing worse than 71.93% of the companies in the same industry.
In the last couple of years the Gross Margin of ICLR has remained more or less at the same level.
Industry RankSector Rank
OM 13.77%
PM (TTM) 9%
GM 29.65%
OM growth 3Y-4.19%
OM growth 5Y-2.83%
PM growth 3Y-14.06%
PM growth 5Y-9.51%
GM growth 3Y0.39%
GM growth 5Y-0.2%
ICLR Yearly Profit, Operating, Gross MarginsICLR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 10 20 30 40

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ICLR is destroying value.
The number of shares outstanding for ICLR has been increased compared to 1 year ago.
The number of shares outstanding for ICLR has been increased compared to 5 years ago.
Compared to 1 year ago, ICLR has an improved debt to assets ratio.
ICLR Yearly Shares OutstandingICLR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
ICLR Yearly Total Debt VS Total AssetsICLR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B

2.2 Solvency

An Altman-Z score of 2.32 indicates that ICLR is not a great score, but indicates only limited risk for bankruptcy at the moment.
ICLR has a Altman-Z score of 2.32. This is comparable to the rest of the industry: ICLR outperforms 52.63% of its industry peers.
The Debt to FCF ratio of ICLR is 2.79, which is a good value as it means it would take ICLR, 2.79 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.79, ICLR belongs to the best of the industry, outperforming 84.21% of the companies in the same industry.
ICLR has a Debt/Equity ratio of 0.35. This is a healthy value indicating a solid balance between debt and equity.
ICLR has a Debt to Equity ratio (0.35) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.79
Altman-Z 2.32
ROIC/WACC0.88
WACC7.13%
ICLR Yearly LT Debt VS Equity VS FCFICLR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B 8B

2.3 Liquidity

A Current Ratio of 1.34 indicates that ICLR should not have too much problems paying its short term obligations.
The Current ratio of ICLR (1.34) is worse than 82.46% of its industry peers.
ICLR has a Quick Ratio of 1.34. This is a normal value and indicates that ICLR is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ICLR (1.34) is worse than 64.91% of its industry peers.
Industry RankSector Rank
Current Ratio 1.34
Quick Ratio 1.34
ICLR Yearly Current Assets VS Current LiabilitesICLR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B

More info and screens

6

3. Growth

3.1 Past

ICLR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.78%, which is quite good.
Measured over the past years, ICLR shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.96% on average per year.
The Revenue has been growing slightly by 3.63% in the past year.
Measured over the past years, ICLR shows a very strong growth in Revenue. The Revenue has been growing by 25.62% on average per year.
EPS 1Y (TTM)12.78%
EPS 3Y25.12%
EPS 5Y15.96%
EPS Q2Q%1.52%
Revenue 1Y (TTM)3.63%
Revenue growth 3Y42.65%
Revenue growth 5Y25.62%
Sales Q2Q%-1.22%

3.2 Future

Based on estimates for the next years, ICLR will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.15% on average per year.
Based on estimates for the next years, ICLR will show a small growth in Revenue. The Revenue will grow by 4.93% on average per year.
EPS Next Y11.68%
EPS Next 2Y9.31%
EPS Next 3Y10.22%
EPS Next 5Y10.15%
Revenue Next Year1.62%
Revenue Next 2Y1.91%
Revenue Next 3Y3.3%
Revenue Next 5Y4.93%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ICLR Yearly Revenue VS EstimatesICLR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B
ICLR Yearly EPS VS EstimatesICLR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 10 20 30

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 14.38 indicates a correct valuation of ICLR.
Based on the Price/Earnings ratio, ICLR is valued cheaper than 100.00% of the companies in the same industry.
ICLR's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.51.
Based on the Price/Forward Earnings ratio of 13.22, the valuation of ICLR can be described as correct.
98.25% of the companies in the same industry are more expensive than ICLR, based on the Price/Forward Earnings ratio.
ICLR's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 93.88.
Industry RankSector Rank
PE 14.38
Fwd PE 13.22
ICLR Price Earnings VS Forward Price EarningsICLR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

96.49% of the companies in the same industry are more expensive than ICLR, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ICLR is valued cheaply inside the industry as 98.25% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 13.55
EV/EBITDA 11.33
ICLR Per share dataICLR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100

4.3 Compensation for Growth

ICLR's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of ICLR may justify a higher PE ratio.
PEG (NY)1.23
PEG (5Y)0.9
EPS Next 2Y9.31%
EPS Next 3Y10.22%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ICLR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ICON PLC

NASDAQ:ICLR (1/30/2025, 4:40:38 PM)

After market: 201.72 0 (0%)

201.72

+3.6 (+1.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)10-23 2024-10-23/amc
Earnings (Next)02-19 2025-02-19/amc
Inst Owners99.8%
Inst Owner Change-0.62%
Ins Owners0.65%
Ins Owner ChangeN/A
Market Cap16.65B
Analysts83.08
Price Target287.28 (42.42%)
Short Float %1.92%
Short Ratio1.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.22%
Min EPS beat(2)-14.41%
Max EPS beat(2)-0.04%
EPS beat(4)0
Avg EPS beat(4)-4.05%
Min EPS beat(4)-14.41%
Max EPS beat(4)-0.04%
EPS beat(8)1
Avg EPS beat(8)-2.37%
EPS beat(12)4
Avg EPS beat(12)-1.66%
EPS beat(16)8
Avg EPS beat(16)-0.37%
Revenue beat(2)0
Avg Revenue beat(2)-4.81%
Min Revenue beat(2)-6.75%
Max Revenue beat(2)-2.88%
Revenue beat(4)0
Avg Revenue beat(4)-3.64%
Min Revenue beat(4)-6.75%
Max Revenue beat(4)-1.81%
Revenue beat(8)0
Avg Revenue beat(8)-2.79%
Revenue beat(12)0
Avg Revenue beat(12)-2.47%
Revenue beat(16)1
Avg Revenue beat(16)-1.49%
PT rev (1m)0.19%
PT rev (3m)-20.91%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.23%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.91%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)-2.67%
Valuation
Industry RankSector Rank
PE 14.38
Fwd PE 13.22
P/S 2
P/FCF 13.55
P/OCF 11.99
P/B 1.7
P/tB N/A
EV/EBITDA 11.33
EPS(TTM)14.03
EY6.96%
EPS(NY)15.26
Fwd EY7.56%
FCF(TTM)14.89
FCFY7.38%
OCF(TTM)16.82
OCFY8.34%
SpS100.62
BVpS118.39
TBVpS-35.33
PEG (NY)1.23
PEG (5Y)0.9
Profitability
Industry RankSector Rank
ROA 4.35%
ROE 7.65%
ROCE 7.95%
ROIC 6.28%
ROICexc 6.6%
ROICexgc 89.85%
OM 13.77%
PM (TTM) 9%
GM 29.65%
FCFM 14.8%
ROA(3y)2.48%
ROA(5y)5.99%
ROE(3y)4.82%
ROE(5y)11.11%
ROIC(3y)4.59%
ROIC(5y)9.41%
ROICexc(3y)4.73%
ROICexc(5y)12.92%
ROICexgc(3y)93.87%
ROICexgc(5y)96.9%
ROCE(3y)5.81%
ROCE(5y)11.91%
ROICexcg growth 3Y9.65%
ROICexcg growth 5Y7.36%
ROICexc growth 3Y-35.19%
ROICexc growth 5Y-24.03%
OM growth 3Y-4.19%
OM growth 5Y-2.83%
PM growth 3Y-14.06%
PM growth 5Y-9.51%
GM growth 3Y0.39%
GM growth 5Y-0.2%
F-Score9
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0.35
Debt/FCF 2.79
Debt/EBITDA 2.02
Cap/Depr 29.44%
Cap/Sales 1.92%
Interest Coverage 250
Cash Conversion 82.4%
Profit Quality 164.33%
Current Ratio 1.34
Quick Ratio 1.34
Altman-Z 2.32
F-Score9
WACC7.13%
ROIC/WACC0.88
Cap/Depr(3y)26.25%
Cap/Depr(5y)47.67%
Cap/Sales(3y)1.76%
Cap/Sales(5y)1.78%
Profit Quality(3y)243.31%
Profit Quality(5y)196.45%
High Growth Momentum
Growth
EPS 1Y (TTM)12.78%
EPS 3Y25.12%
EPS 5Y15.96%
EPS Q2Q%1.52%
EPS Next Y11.68%
EPS Next 2Y9.31%
EPS Next 3Y10.22%
EPS Next 5Y10.15%
Revenue 1Y (TTM)3.63%
Revenue growth 3Y42.65%
Revenue growth 5Y25.62%
Sales Q2Q%-1.22%
Revenue Next Year1.62%
Revenue Next 2Y1.91%
Revenue Next 3Y3.3%
Revenue Next 5Y4.93%
EBIT growth 1Y16.34%
EBIT growth 3Y36.67%
EBIT growth 5Y22.06%
EBIT Next Year15.61%
EBIT Next 3Y8.54%
EBIT Next 5Y8.47%
FCF growth 1Y57.62%
FCF growth 3Y25.44%
FCF growth 5Y35.89%
OCF growth 1Y52.16%
OCF growth 3Y26.91%
OCF growth 5Y34.01%